Silence Therapeutics Raises $175M in Upsized Public Offering
Event summary
- Silence Therapeutics priced a $175M underwritten public offering of 12.96M ADSs at $13.50 per share.
- Underwriters have a 30-day option to purchase an additional 1.94M ADSs.
- The offering is expected to close on August 13, 2026.
- Proceeds will be used for general corporate purposes and to advance the company's siRNA pipeline.
The big picture
Silence Therapeutics' $175M offering reflects the growing investor appetite for innovative RNA-based therapies. The company's mRNAi GOLD™ platform positions it in a competitive biotech landscape, where precision-engineered medicines are gaining traction. This funding round could bolster Silence's pipeline and market standing as it competes with larger players in the siRNA space.
What we're watching
- Pipeline Advancement
- How the capital infusion will accelerate Silence Therapeutics' clinical-stage siRNA programs.
- Market Positioning
- Whether the upsized offering signals increased investor confidence in RNA therapeutics.
- Execution Risk
- The pace at which Silence Therapeutics can translate funding into tangible clinical milestones.
Related topics